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The  absorption  and  excretion  of the  insect  repellent  IR3535® was  studied  in  human  subjects  after  dermal  application.
IR3535® was  rapidly  metabolized  to  the corresponding  acid.
Based  on  the recovery  of  IR3535® free  acid,  the skin  penetration  rate of  IR3535® is  13.3%  in humans  after  dermal  application.
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a  b  s  t  r  a  c  t
The  absorption  and  excretion  of  the  insect  repellent  IR3535® was  studied  in  human  subjects  (ﬁve  males
and  ﬁve  females)  after  dermal  application  of approx.  3  g  of  a formulation  containing  20%  IR3535®,  i.e. the
amounts  of  IR3535® applied  were  between  1.94  and  3.4 mmol/person  (418–731  mg/person).  Blood  and
urinary  concentrations  of  IR3535® and  its  only  metabolite,  IR3535®-free  acid,  were  determined  over  time.
In  plasma,  concentrations  of  the  parent  compound  IR3535® were  at or below  the limit  of  quantiﬁcation
(0.037  mol/L).  IR3535®-free  acid peaked  in  plasma  samples  2–6  h after  dermal  application.  Cmax mean
values  were  5.7  mol/L  in males,  3.0  mol/L  in  females  and  4.2  mol/L  in  all volunteers.  Mean  AUC  val-
ues  were  41.6,  24.5  and  33.9  mol  L−1 h  in males,  females  and  all subjects,  respectively.  In urine  samples
from  all  human  subjects,  both  IR3535® and  IR3535®-free  acid  were  detectable,  however,  only  very  small
amounts  of  IR3535® were  found.  Concentrations  of IR3535®-free  acid  were  several  thousand-fold  higher
than  the  parent  compound  and peaked  at the  ﬁrst  two  sampling  points  (4 h and  8 h after  dermal  applica-
tion).  Overall,  IR3535® and  IR3535®-free  acid excreted  with  urine  over  48  h  representing  13.3 ± 3.05%  of
the  dose  applied.  Since  IR3535® is  rapidly  and extensively  metabolized,  and  IR3535®-free  acid  has  a  low
molecular  weight  and  high  water  solubility,  it is expected  that  urinary  excretion  of  IR3535®-free  acid
and  IR3535® represents  the  total  extent  of  absorption  of  IR3535® in  humans.  Based on the  results  of  this
study,  the  skin  penetration  rate  of  IR3535® is  13.3%  in  humans  after  dermal  application.. Introduction
IR3535® [3-(N-n-butyl-N-acetyl)-aminopropionic acid
thylester, 1, Fig. 1] is a derivative of the natural amino acid
-alanine and an effective insect repellent (Carroll et al., 2010;
arroll, 2008; Naucke et al., 2006). IR3535® did not show systemic
oxicity after single and repeated dermal or oral administration
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in rats and dogs, respectively (Pﬁster et al., 1996; Schmitt, 2006).
Based on several in vitro and in vivo studies (rats, rabbits), a mean
dermal penetration rate of approx. 30% of the applied dose was
found for IR3535® (Arcelin and Stegehuis, 1996; Burri, 1996a,b;
van de Sandt, 2002). As other esters with widespread dermal
application (Goebel et al., 2009; Jewell et al., 2007; Prusakiewicz
et al., 2006; Williams, 2008) absorbed IR3535® is rapidly metab-
olized by ester cleavage and is rapidly excreted as the free acid
[3-(N-n-butyl-N-acetyl)-aminopropionic acid, 2, Fig. 1] with urine
(Burri, 1996a,b; Ladstetter, 1996; Schmitt, 2006).
Open access under CC BY-NC-ND license.Since a study in humans under realistic conditions is consid-
ered the method of choice to assess dermal exposure (Boogaard,
2008), the aim of this study was  to determine extent of absorp-
tion and kinetics of excretion of IR3535® in humans after dermal
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Fig. 1. Biotransformation of IR3535® 1 to IR3535®-free acid 2 in mammals. 2 is the
only  known metabolite of 1 in mammals.
Table 1
Composition of the formulation EUS-26-15.
Ingredient INCI name [%]
IR3535® Ethyl butylacetylaminopropionate 20.0%
Polyethylene glycol 400 PEG-8 5.0%
Arlamol E PPG-15 stearyl ether 1.0%
Ethanol Alcohol 35.0%
Polyethylene glycol 1500 PEG-32 4.0%
PVP/VA W-735 PVP/VA copolymer 2.0%
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Table 3
Mass spectrometric parameters (MS–MS-transitions, declustering potential and col-
lision energy) used to quantify IR3535® and its metabolite.
Metabolite Transition
[m/z]
Declustering
potential [V]
Collision
energy [V]
IR3535® 216–170
216–86
33 25
IR3535®-free acid 188–86
188–170
33 25Tween 20 Polysorbate 20 1.5%
Water, demineralized Aqua(Water) 31.5%
pplication. The toxicokinetics of IR3535® were determined in ﬁve
ale and ﬁve female human subjects after application of a repel-
ent formulation containing 20% IR3535®. Urine and blood samples
ere taken at predetermined time points and the concentrations of
R3535® 1 and IR3535®-free acid 2 were determined by LC–MS/MS
n these samples.
. Materials and methods
.1. Chemicals
The formulation containing 20% (w/w) IR3535® (name: EUS26-15) was  sup-
lied by Merck KGaA (Darmstadt, Germany) in pump spray bottles. The composition
f the formulation is provided in Table 1. Received bottles were stored protected
rom light at room temperature. They were used as received. For the preparation
f  the spray formulation, batch 1887B006 of IR3535® (MW = 215.29 g/mol) was
sed (purity 99.6%). This batch was also used as external standard. ®IR3535-free
cid  (MW  = 187.24 g/mol) was  received from Merck KGaA as external standard. All
ther reagents and solvents were reagent grade or better and obtained from several
ommercial suppliers.
.2. Volunteers
Human subjects (ﬁve males and ﬁve females) were included in this study. All
ubjects in the study had to refrain from alcoholic beverages and medicinal drugs
wo days before and throughout the experiment. Subjects did not abuse alcohol and
ere non-smokers; for details on participating subjects, see Table 2. Subjects were
ealthy as judged by detailed medical anamnesis and had normal liver and kidney
unction based on clinical blood chemistry. The study was carried out according to
he Declaration of Helsinki, after approval by the Regional Ethical Committee of the
niversity of Würzburg, Germany, and after written informed consent by the human
ubjects participating.
able 2
haracterization of human subjects participating in the study.
Subjecta Gender Age Height [cm] Body weight [kg]
A Male 20 180 80
B  Male 24 180 83
C  Male 23 173 72
D  Male 21 181 70
E  Male 21 185 83
F  Female 25 179 62
G  Female 25 164 56
H  Female 26 172 58
K  Female 32 158 50
L Female 28 170 57
a Designations I and J were not used for volunteers to avoid any confusion.Phenacetin as
internal standard
180–110
180–138
33 25
2.3. Exposure of human subjects to IR3535®
The IR3535® containing formulation was applied to the skin of the ﬁve healthy
male and ﬁve healthy female subjects. In accordance to a typical exposure scenario
approx. 3 g of the formulation were applied to hands, arms, legs, feet, face and neck
of  each volunteer (approx. 50% of body surface). At least 26 piston hubs were applied
from the pump spray bottle and residual content of IR3535® in the bottle was deter-
mined thereafter by weighing. Subjects were permitted to take showers 12 h after
application of the formulation.
2.4. Sampling
Urine samples from the subjects were collected in predetermined intervals (one
hour before application, and then 4, 8, 12, 16, 24, 36 and 48 h after application).
After determination of the total urine volume, two  aliquots of 50 ml were stored
at  −20 ◦C. Blood samples (10 mL)  were also taken at predeﬁned time points (24 h
before application, directly after application of IR3535® , and 0.5, 1, 1.5, 2, 4, 6, 8 and
24  h after application of IR3535®) by the supervising physician with heparinized
syringes. Blood samples were immediately centrifuged for 15 min at 1 560 x g to
separate erythrocytes and plasma. Plasma samples were then rapidly frozen and
stored at −70 ◦C until further sample preparation and analysis.
2.5. Analytical procedures
IR3535® 1 and IR3535®-free acid 2 in urine and plasma were determined by
LC–MS/MS using electrospray ionization. Processed plasma and urine samples were
separated on a ReproSil Pur ODS3 HPLC column (2 mm × 150 mm;  5 m;  Maisch,
Ammerbuch, Germany) using an Agilent 1100 autosampler and an Agilent 1100
HPLC-pump (Agilent, Waldbronn, Germany). Separation was performed by gradient
elution with water containing 0.1% formic acid (solvent A) and methanol (solvent
B)  using the following conditions: 90% A, 10% B, isocratic for 2 min, linear increase
to  100% B within 10 min, followed by 100% B for 5 min, at a ﬂow-rate of 200 L/min.
The HPLC-system was directly coupled to a triple stage quadrupole mass spec-
trometer (API 2000 Q-Trap, Applied Biosystems, Darmstadt, Germany). Analytes
were detected in the positive-ion mode at a vaporizer temperature of 400 ◦C and
a  TurboIon® Spray voltage of +4.0 kV. Spectral data were recorded with nitrogen
as  collision gas (CAD = 4) in the multiple reaction monitoring (MRM)  mode. Mass
transitions monitored during the separation are listed in Table 3.
The following mass transitions were used for quantiﬁcation: m/z  180–110 for
the  internal standard phenacetin, m/z  216–170 for IR3535® 1, and m/z  188–86 for
IR3535®-free acid 2.
2.6. Sample preparation
Quantiﬁcation of IR3535® 1 and IR3535®-free acid 2 in human plasma was per-
formed in 200 L aliquots of the plasma samples after thawing at 4 ◦C for 2 h and
fortiﬁcation with 5 L of the internal standard phenacetin (1 mg/L in water) (Kress,
2009). Subsequently, 200 L of methanol were added to each sample. Samples were
then vortexed and centrifuged for 20 min  at 20.000 × g at 4 ◦C. The supernatants
(350  L) from this centrifugation were stored at −20 ◦C; the obtained pellet was
treated with an additional 200 L of methanol to recover residual IR3535® 1 and
IR3535®-free acid 2. The obtained supernatant from the second centrifugation was
combined with the supernatant from the ﬁrst centrifugation; the combined samples
were vortexed again and subject to another centrifugation to precipitate remaining
proteins. The supernatant from the last centrifugation (400 L) was then transferred
into glass autosampler vials and 10 L were analyzed by LC–MS/MS.
For quantitative analysis of IR3535® 1 and IR3535®-free acid 2 in urine, stored
urine samples were thawed and 0.5 mL  of the samples were fortiﬁed with the
internal standard phenacetin (5 L of a solution containing 1 mg/L in water). Urine
◦samples were subjected to centrifugation at 15.000 × g for 10 min  at 4 C and 10 L
of  the supernatant were then analyzed by LC–MS/MS. To quantify IR3535®-free acid
2,  samples often required dilution of up to 10,000 fold since the concentrations of 2
in  undiluted urine samples were outside of the linear range of the calibration curve.
248 T.H. Broschard et al. / Toxicology Letters 218 (2013) 246– 252
Table 4
Plasma levels of IR3535®-free acid in volunteers at different time points (expressed as g/L).
Time [h] IR3535®-free acid in plasma [g/L]
Male volunteers Female volunteers Mean M + F
A B C D E Mean M F G H K L Mean F
−24 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD
0a 11.44 17.85 3.80 6.85 5.25 9.04 ± 5.70 6.00 7.34 13.48 6.38 6.57 7.95 ± 3.13 8.50 ± 4.37
0.5  185.35 401.50 69.85 60.50 484.00 240.24 ± 193.50 97.63 78.38 136.40 84.15 52.25 89.76 ± 30.84 165.00 ± 152.82
1 638.00 951.50 125.68 148.50 783.75 529.49 ± 375.08 173.80 251.08 305.25 152.90 117.43 200.09 ± 76.50 364.79 ± 308.65
1.5  690.25 1537.25 154.55 166.38 962.50 702.19 ± 581.43 253.55 442.75 467.50 185.35 183.70 306.57 ± 138.79 504.38 ± 449.76
2 1584.00 1960.75 153.73 248.33 1465.75 1082.51 ± 825.86 346.50 580.25 855.25 283.25 221.93 457.44 ± 260.51 769.97 ± 664.70
4  1185.25 2373.25 182.60 299.75 929.50 994.07 ± 877.98 368.50 808.50 508.75 343.75 n.ab 507.38 ± 213.49 777.76 ± 684.34
6  726.00 965.25 181.50 484.00 863.50 644.05 ± 315.28 310.75 442.75 530.75 668.25 880.00 566.50 ± 218.31 605.28 ± 258.90
8  621.50 723.25 200.20 209.83 265.93 404.14 ± 248.76 219.73 n.a. 506.00 172.70 n.a. 299.48 ± 180.39 364.89 ± 218.16
24  11.72 47.03 17.19 10.70 16.80 20.69 ± 15.01 12.82 3.38 6.33 9.79 n.a. 8.08 ± 4.10 15.08 ± 12.77
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b n.a. = not analyzed.
.7. Quantiﬁcation
All quantiﬁcations were based on the area of the peaks of IR3535® 1 and
R3535®-free acid 2 relative to the area of the internal standard phenacetin. Quan-
iﬁcation of IR3535® 1 and IR3535®-free acid 2 was  based on calibration curves
btained after fortiﬁcation of plasma and urine samples from unexposed human
ubjects with internal standard, IR3535® 1 and IR3535®-free acid 2 (matrix-matched
tandards). The analytical methods for determination of IR3535® 1 and IR3535®-free
cid  2 in urine and plasma were validated. Calibration curves were calculated from
ve  to nine data points using Analyst 1.4.1 (Applied Biosystems). The R2-values of the
alibration curves were >0.99. Limit of quantiﬁcation (LOQ) for IR3535® was  8 g/L
0.037 mol/L) in plasma and 3 g/L (0.014 mol/L) in urine; LOQ for IR3535®-free
cid 2 was  5 g/L (0.03 mol/L) in plasma and 2 g/L (0.01 mol/L) in urine. Limit
f  detection (LOD) for IR3535® was 1.6 g/L (0.007 mol/L) in plasma and 0.6 g/L
0.003 mol/L) in urine; LOD for IR3535®-free acid 2 was 1 g/L (0.006 mol/L)
n  plasma and 0.4 g/L (0.002 mol/L) in urine. Standard deviations (mean ± SD)
ere calculated using MicrosoftExcel® spreadsheets and default settings. Polynoms
iven for best ﬁt by MicrosoftExcel® were transferred into “Functions” (Numerical-
athematics.com), AUCs were calculated from the mean of each time point using
inetica, version 4.4.1. The AUC values of the parent IR3535® were not calculated
s  the plasma concentrations of this compound were at the levels of the LOQ and,
hus, negligible compared to the IR3535®-free acid 2.
. Results
.1. Application of IR3535®
The ten subjects applied between 2.09 and 3.66 g formulation
orresponding to 1.94 to 3.40 mmol  IR3535®/person (see Table 7).
ll subjects showered 12 h after application as permitted. During
he course of the study, the volunteers did not report any adverse
ndings or signs of irritation attributable to the application of the
pray formulation containing 20% IR3535®.
.2. Plasma levels of IR3535® and its metabolite
Blood samples were taken at predetermined time intervals (24 h
efore application as control and at 0 (shortly after application),
.5, 1, 1.5, 2, 4, 6, 8 and 24 h) after dermal application of a formu-
ation containing 20% (w/w) IR3535® to determine plasma levels
f IR3535® 1 and IR3535®-free acid 2, the only known mammalian
etabolite (Arcelin and Stegehuis, 1996; Ladstetter, 1996; van Dijk,
996). Kinetics of elimination from plasma and urine were deter-
ined in ﬁve male and ﬁve female subjects.
Neither IR3535® 1 nor IR3535®-free acid 2 were detected in
lasma samples collected before the dermal application of IR3535®
. In all plasma samples collected after the application, the parent
ompound IR3535® was detected in trace amounts in samples col-
ected at most time points; however, the peak areas were close
o, at, or below the LOQ of 8 g/L. Moreover, sample carryover
ccurred during the analyses of plasma samples: IR3535® 1 was
lso detected in low concentrations (around the LOQ) when controlsamples (plasma from unexposed human subjects) were analyzed
after injecting calibration samples. Therefore, an exact quantiﬁca-
tion of IR3535® 1 in plasma samples was not possible.
A typical chromatogram (with an IR3535®-free acid 2 peak)
obtained from a plasma sample of an individual after dermal appli-
cation of IR3535® is shown in Fig. 2.
After application of IR3535® 1 to the human subjects, a single
peak was obtained showing the typical mass transition of IR3535®-
free acid 2 at the expected retention time (Fig. 2). Peaks at this
retention time with the expected relative intensities were also seen
for the other mass transition monitored conﬁrming conclusively
the presence of IR3535®-free acid (data not shown).
The concentrations of IR3535®-free acid 2 were well above the
LOQ (5 g/L or 0.03 mol/L) in all plasma samples collected after
dermal administration of IR3535® 1 (see Tables 4 and 5).
The time courses of plasma concentrations of IR3535®-free acid
2 in the subjects are shown in Tables 4 and 5 and Fig. 3. Peak
plasma levels (Cmax) of IR3535®-free acid 2 were reached 2 h to
6 h after dermal application (mean values: 5.7 mol/L in males;
3.0 mol/L in females; 4.2 mol/L in all human subjects participat-
ing). After the 4 h sampling point, concentrations of IR3535®-free
acid 2 decreased following 1st order kinetics with a half-life of app.
2–4 h in all volunteers to reach concentrations close to the limit of
quantiﬁcation (LOQ: 0.03 mol/L) at the last collection time point
of 24 h after the application.
The mean AUC-values of IR3535®-free acid 2 for males, females
and all participants are summarized in Table 6.
3.3. Urine levels of IR3535® and its metabolite
In urine samples collected from the human subjects after der-
mal  application of IR3535® 1 at predetermined time intervals, both
IR3535® 1 and IR3535®-free acid 2 were identiﬁed by LC–MS/MS
due to the presence of the characteristic mass transitions at the
expected retention times (Fig. 4). IR3535® 1 and IR3535®-free
acid 2 were present in concentrations above the LOQ  in all col-
lected urine samples after application of IR3535®: In the urine
sample taken before application the concentration of IR3535® 1
and IR3535®-free acid 2 was  below the LOD of 0.6 g/L (IR3535®
1) and 0.4 g/L (IR3535®-free acid 2), respectively.
The kinetics of excretion of IR3535® 1 and IR3535®-free acid
2 is shown in Fig. 5. Concentrations of parent IR3535® 1 in urine
were very low (more then 4 orders of magnitude lower than those
of IR3535®-free acid 2) as expected from the rapid metabolism
to IR3535®-free acid 2. Peak concentrations of IR3535® 1 and
IR3535®-free acid 2 were observed in urine samples at the ﬁrst
two collection points four and eight hours after dermal application
of IR3535® 1 (Fig. 5).
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Fig. 2. Typical chromatogram from a plasma sample of a human subject after dermal application of IR3535® 1. The peak at 14.8 min represents IR3535®-free acid 2.
Table 5
Plasma levels of IR3535®-free acid in volunteers at different time points (expressed as mol/L).
Time [h] IR3535®-free acid in plasma [mol/L]
Male volunteers Female volunteers Mean M + F
A B C D E Mean M F G H K L Mean F
−24 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD
0a 0.061 0.095 0.020 0.037 0.028 0.048 ± 0.030 0.032 0.039 0.072 0.034 0.035 0.042 ± 0.021 0.045 ± 0.023
0.5  0.990 2.145 0.373 0.323 2.585 1.283 ± 1.034 0.522 0.419 0.729 0.450 0.279 0.479 ± 0.158 0.881 ± 0.816
1  3.408 5.083 0.671 0.793 4.187 2.828 ± 2.004 0.928 1.341 1.631 0.817 0.627 1.069 ± 0.353 1.949 ± 1.649
1.5 3.687 8.212 0.826 0.889 5.142 3.751 ± 3.106 1.354 2.365 2.497 0.990 0.981 1.638 ± 0.625 2.694 ± 2.403
2  8.462 10.474 0.821 1.327 7.830 5.783 ± 4.412 1.851 3.100 4.569 1.513 1.185 2.444 ± 1.360 4.113 ± 3.551
4 6.331  12.678 0.975 1.601 4.965 5.310 ± 4.690 1.968 4.319 2.718 1.836 n.a.b 2.710 ± 1.201 4.155 ± 3.656
6  3.878 5.156 0.970 2.585 4.613 3.440 ± 1.684 1.660 2.365 2.835 3.570 4.701 3.026 ± 0.592 3.233 ± 1.383
8  3.320 3.864 1.069 1.121 1.421 2.159 ± 1.329 1.174 n.a. 2.703 0.923 n.a. 1.600 ± 1.081 1.949 ± 1.165
24  0.063 0.251 0.092 0.057 0.090 0.110 ± 0.080 0.068 0.018 0.034 0.052 n.a. 0.043 ± 0.026 0.081 ± 0.068
a Shortly after application.
b n.a. = not analyzed.
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Fig. 3. Mean concentrations of IR3535®-free acid 2 (mean ± SD) in plasma samples from ﬁve male () and ﬁve female human subjects () after dermal application of a
formulation containing 20% IR3535® 1. The mean concentrations of IR3535®-free acid 2 in all subjects is also provided ().
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Fig. 4. Typical chromatograms for urine samples from human subjects after dermal application of IR3535® 1. The upper panel represents the transition selected for quantiﬁ-
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Excretion of IR3535®-free acid 2 declined rapidly to reach
oncentrations close to the LOQ 48 h after application, half-life
f urinary excretion was approx. six hours. Only 2.9 moles of
R3535®-free acid 2 were excreted in the time interval between
6 and 48 h after dermal application of IR3535®. Based on the total
mount of IR3535® 1 and IR3535®-free acid 2 excreted in urine, the
xtent of absorption of IR3535® after dermal application is 13.3%
Table 7).
. Discussion
This study used a realistic exposure scenario since the chemical
nder study was applied to the skin as expected under typical use
atterns in humans. The results thus give information on systemic
oses received. Therefore, due to the large amounts of applied, 14C-
abeled IR3535® could not be used. Based on urinary recovery and
able 6
UC-values for IR3535®-free acid 2 in humans after dermal application of 2–3 g of
 formulation containing 20% IR3535® 1.
AUC values [mol  × L−1 × h]a
Males 41.6
Females 24.5
All human subjects 33.9
AUC values were calculated using Kinetica, version 4.4.1cid 2. For analysis of IR3535®-free acid 2, urine samples were diluted by 100–1000
kinetics of excretion, IR3535® 1 is rapidly metabolized in humans
and the resulting metabolite, IR3535®-free acid 2, formed by ester
cleavage, is rapidly excreted. The formation of IR3535®-free acid
2 as the only metabolite of IR3535® 1 is well characterized and
has been studied in vitro and in vivo using radiolabeled IR3535®
1, which was rapidly and completely metabolized by hepatocytes
of rats and humans resulting in IR3535®-free acid 2 as the only
metabolite. IR3535®-free acid 2 itself was  not further metabolized
(Ladstetter, 1996). In addition, IR3535®-free acid 2 was the only
metabolite detected in several animal species treated with 14C-
labeled IR3535® 1 orally and/or topically (Arcelin and Stegehuis,
1996; Ladstetter, 1996; van Dijk, 1996). Only very low amounts
of non metabolized IR3535® 1 were found in urine and in plasma
samples suggesting intensive biotransformation as already shown
in the toxicokinetics studies with IR3535® in experimental animals.
The IR3535®-free acid 2 is also expected as the only metabolite of
IR3535® 1 in humans, since other metabolic pathways are unlikely
considering the structure of IR3535® 1. Unspeciﬁc esterases are
present in skin, in erythrocytes and in plasma of humans (Baron and
Merk, 2001; Parkinson and Ogilvie, 2008); therefore, most of the
absorbed IR3535® is rapidly metabolized explaining the very low
blood levels observed in this study. Biotransformation of IR3535®1 may already occur in the skin, the formed IR3535® -free acid
2 may  be slowly cleared from the skin. After dermal application
of 1023 g/cm2 equivalents, IR3535® was  slowly cleared from rat
skin with an approximately 50% reduction in residual concentration
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mig. 5. Urinary excretion (total recovery over urine collection period) of IR3535® 1 (A
fter dermal application of a formulation containing 20% IR3535® . Total excretion w
ample.
ccuring over a time period of 48 h. The identity of the radioactivity
®emaining in skin was not determined. The metabolite IR3535 -
ree acid 2 is expected to be exclusively excreted with urine due to
ts high polarity and molecular weight well below the threshold for
iliary elimination in humans (MW  550 Da). Moreover, IR3535® 1
able 7
ass balance of IR3535® 1 in human subjects after dermal application. Mass balance d
etabolite, IR3535®-free acid 2.
Volunteersc Sex Dose of
formulation
received [g]
Amount of IR3535a
applied [mol]
IR3535 
[mol]
Volunteer A M 2.9807 2769.01 0.028 
Volunteer B M 3.0140 2799.94 0.052 
Volunteer C M 2.5763 2393.33 0.045 
Volunteer D M 2.8099 2610.34 0.024 
Volunteer E M 2.9107 2703.98 0.046 
Volunteer F F 2.0928 1944.17 0.020 
Volunteer G F 2.6950 2503.60 0.036 
Volunteer H F 3.6557 3396.07 0.044 
Volunteer K F 2.2820 2119.93 0.025 
Volunteer L F 2.8461 2643.97 0.034 
Mean ± SD 2.7863 ± 0.43 2588.43 ± 398.1 0.035 ±
a Molecular weight IR3535®: 215.29 g/mol.
b Molecular weight IR3535® free acid: 187.24 g/mol.
c Designations I and J were not used for volunteers to avoid any confusion. IR3535®-free acid 2 (B) (mean ± SD) in 5 male () and 5 female human subjects ()
tained by multiplication of urine concentration and urine volume of the respective
is of insufﬁcient volatility to be cleared to a larger extent by exha-
lation. The data on plasma concentrations show a rapid absorption
and excretion of dermally applied IR3535® since the concentra-
tion of IR3535®-free acid 2 in plasma already decreases after 4 h
and reaches the LOQ at the 24 h sampling point. Despite applying
ata are based on summarized urinary excretion of IR3535® 1 and its only known
in urine IR3535-free acidb
in urine [mol]
Total Recovery in
urine [mol]
Absorption [%]
399.754 399.782 14.44
545.450 545.502 19.48
287.118 287.163 12.00
240.333 240.357 9.21
290.590 290.636 10.75
309.015 309.036 15.90
367.069 367.105 14.66
493.004 493.047 14.52
243.271 243.296 11.48
286.851 286.885 10.85
 0.011 346.246 ± 104.27 346.281 ± 104.27 13.3 ± 2.5
2 logy L
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B52 T.H. Broschard et al. / Toxico
ery similar doses of IR3535® to the skin and almost identical mean
ecoveries of IR3535®-free acid 2 in urine, peak plasma concentra-
ions of IR3535®-free acid 2 were twofold higher in male human
ubjects as compared to the female humans subjects in the study.
he basis for these differences is not known and may  be due to gen-
er differences in absorption, distribution, and biotransformation
f IR3535®. Due to the rapid absorption and elimination, the recov-
red amount of IR3535®-free acid 2 in urine represents the extent
f absorption of IR3535® 1 through the skin in humans. Absorp-
ion of IR3535® 1 in humans therefore is 13.3% (Table 6) which is
ess than half of that observed through the skin in experimental
nimals or in vitro. The formulation contains the known skin pene-
ration enhancers ethanol, PEG-8 and PEG-32 at concentrations of
5.0, 5.0 and 4.0%, respectively (Table 1). Therefore, the determined
enetration rate of 13.3% for IR3535 can reasonably be considered
s a worst-case value for skin absorption.
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